ACM Biolabs
6 articles about ACM Biolabs
-
ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001
9/5/2023
ACM Biolabs, a biotechnology company using its next-generation polymer-based delivery platform to develop new nano formulations for use in multiple therapeutic fields, announced positive topline results from a Phase I trial of ACM-001, the Company's first clinical-stage development program.
-
ACM Biolabs Further Strengthens Leadership, Appoints David Lawrence to Board of Directors
4/11/2023
ACM Biolabs announces the appointment of David Lawrence as Non-Executive Director.
-
InMed updated its INM-755 for patients with epidermolysis bullosa, Seagen and Astellas announced positive topline results for Padcev with Merck’s Keytruda, and more.
-
As part of 'Operation Nasal Vaccine' to counter COVID-19 spread, ACM-001 booster vaccine administered to first subject in phase 1 safety and immunogenicity trial
7/29/2022
ACM Biolabs announced that the first subject has been dosed in the first–in–human Phase 1 trial of its clinical candidate vaccine, ACM-001, a 2nd generation adjuvanted SARS-CoV-2 spike protein vaccine with broad protection against variants of concerns, including delta and omicron demonstrated in a variety of preclinical studies.
-
Second Positive PED Animal Trials Completed Using ACM Biolabs' Technology
10/4/2016
-
Positive Animal Trials Completed Using ACM Biolabs’ Technology
2/3/2016